109 selected records with a cited source date in 2015. This archive is selective and does not imply continuous monitoring or complete historical coverage.
PeptideScanner retained ClinicalTrials.gov record NCT00663403 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-12-30, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT02640976 at 2026-11-15T22:02:39.332Z. Its registry update date was 2015-12-29, and PeptideScanner's reviewed identity mapping was cetrorelix.
The Federal Register published proposed rule 2015-32246, attributed to FDA and its parent HHS department, on 2015-12-23. Its official title is “Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph,” and PeptideScanner's exact reviewed identity mapping connects the document to Glatiramer.
PeptideScanner retained ClinicalTrials.gov record NCT01917773 at 2026-07-30T21:39:57.679Z. Its registry update date was 2015-12-21, and PeptideScanner's reviewed identity mapping was octreotide.
DailyMed lists Structured Product Labeling version 9 for the reviewed Linaclotide label family with a published date of 2015-12-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PubMed lists PMID 26671082 in Journal of the neurological sciences as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2015-10-08 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT02020629 at 2026-07-30T21:39:57.678Z. Its registry update date was 2015-12-15, and PeptideScanner's reviewed identity mapping was lixisenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00076544 at 2026-07-30T21:39:57.683Z. Its registry update date was 2015-12-14, and PeptideScanner's reviewed identity mapping was ziconotide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 206127 with status AP dated 2015-12-08, and names eptifibatide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT02622906 at 2026-11-15T22:05:38.400Z. Its registry update date was 2015-12-07, and PeptideScanner's reviewed identity mapping was pasireotide.
DailyMed lists Structured Product Labeling version 8 for the reviewed Linaclotide label family with a published date of 2015-12-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00225433 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT01155206 at 2026-07-30T21:39:57.683Z. Its registry update date was 2015-12-02, and PeptideScanner's reviewed identity mapping was glucagon.
PubMed lists PMID 16149565 in Nihon rinsho. Japanese journal of clinical medicine as Journal Article, Review, with publication-date metadata of 2005-08 (month precision). PeptideScanner associated the retained record with the identity slug secretin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 22449210 in Expert review of neurotherapeutics as Journal Article, Review, with publication-date metadata of 2012-04 (month precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 23709209 in Seminars in neurology as Journal Article, Review, with publication-date metadata of 2013-05-25 (day precision). PeptideScanner associated the retained record with the identity slug glatiramer-acetate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 6358816 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 1983-11-25 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 22082230 in The journal of sexual medicine as Letter, with publication-date metadata of 2011-11-14 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 26364391 in Medizinische Monatsschrift fur Pharmazeuten as Journal Article, with publication-date metadata of 2015-04 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 20452924 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2010 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 20456108 in Transplant international : official journal of the European Society for Organ Transplantation as Comment, Journal Article, with publication-date metadata of 2010-03-01 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 21388446 in Diabetic medicine : a journal of the British Diabetic Association as Case Reports, Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2011-06 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 21595276 in Nihon rinsho. Japanese journal of clinical medicine as English Abstract, Journal Article, Review, with publication-date metadata of 2011-05 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 22165195 in Lijecnicki vjesnik as English Abstract, Journal Article, Review, with publication-date metadata of 2011 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 22257418 in Diabetes research and clinical practice as Case Reports, Letter, with publication-date metadata of 2012-01-16 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 23507272 in Medicina clinica as Case Reports, Letter, with publication-date metadata of 2013-03-15 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 23834125 in The British journal of dermatology as Case Reports, Letter, with publication-date metadata of 2013-07 (month precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 24315766 in American journal of kidney diseases : the official journal of the National Kidney Foundation as Case Reports, Letter, with publication-date metadata of 2013-12-04 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 25455831 in Diabetes & metabolism as Case Reports, Letter, with publication-date metadata of 2014-11-06 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained PubMed bibliographic metadata for PMID 22997980 at 2026-07-30T21:41:09.514Z. PubMed recorded a metadata revision date of 2015-11-19 and an Entrez history date of 2012-09-25. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 14999221 at 2026-07-30T21:41:07.288Z. PubMed recorded a metadata revision date of 2015-11-19 and an Entrez history date of 2004-03-05. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained PubMed bibliographic metadata for PMID 15833522 at 2026-07-30T21:41:07.293Z. PubMed recorded a metadata revision date of 2015-11-19 and an Entrez history date of 2005-04-19. PeptideScanner associated this retained record with the identity slug bremelanotide. These dates describe PubMed metadata history, not the article's original publication date.
DailyMed lists Structured Product Labeling version 13 for the reviewed Dulaglutide label family with a published date of 2015-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00710814 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-11-16, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT01413542 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-11-04, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01160315 at 2026-11-15T21:49:16.513Z. Its registry update date was 2015-10-30, and PeptideScanner's reviewed identity mapping was triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT02102646 at 2026-11-15T21:49:16.513Z. Its registry update date was 2015-10-28, and PeptideScanner's reviewed identity mapping was triptorelin.
PubMed lists PMID 25345350 in Biotechnology and applied biochemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-08-06 (day precision). PeptideScanner associated the retained record with the identity slug peg-mgf. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT01223937 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-10-15, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT01262456 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-10-15, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00205426 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-10-14, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT01753856 at 2026-07-30T21:39:57.682Z. Its registry update date was 2015-10-08, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01360424 at 2026-07-30T21:41:27.767Z. Its registry update date was 2015-09-29, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01785043 at 2026-07-30T21:41:27.766Z. Its registry update date was 2015-09-15, and PeptideScanner's reviewed identity mapping was liraglutide.
The Federal Register published notice 2015-22673, attributed to FDA and its parent HHS department, on 2015-09-09. Its official title is “Determination That GLUCAGON (Glucagon Hydrochloride) for Injection, Equivalent to 1 Milligram Base/Vial and Equivalent to 10 Milligram Base/Vial, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon.
PeptideScanner retained ClinicalTrials.gov record NCT01606072 at 2026-11-16T01:33:21.554Z. Its registry update date was 2015-08-28, and PeptideScanner's reviewed identity mapping was desmopressin.
PeptideScanner retained ClinicalTrials.gov record NCT00005006 at 2026-07-30T21:41:27.764Z. Its registry update date was 2015-08-19, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00487188 at 2026-11-16T01:41:15.051Z. Its registry update date was 2015-08-13, and PeptideScanner's reviewed identity mapping was enfuvirtide.
PeptideScanner retained ClinicalTrials.gov record NCT00473265 at 2026-07-30T21:41:27.762Z. Its registry update date was 2015-07-16, and PeptideScanner's reviewed identity mapping was teriparatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090811 with status AP dated 2015-07-14, and names bivalirudin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090816 with status AP dated 2015-07-14, and names bivalirudin among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT01387347 at 2026-11-16T01:44:56.605Z. Its registry update date was 2015-07-10, and PeptideScanner's reviewed identity mapping was thymosin-beta-4.
PeptideScanner retained ClinicalTrials.gov record NCT00405548 at 2026-11-16T01:39:41.882Z. Its registry update date was 2015-07-01, and PeptideScanner's reviewed identity mapping was nesiritide.
PeptideScanner retained ClinicalTrials.gov record NCT00108732 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-06-30, and PeptideScanner's reviewed identity mapping was goserelin.
PubMed lists PMID 26028173 in Expert review of cardiovascular therapy as Journal Article, Review, with publication-date metadata of 2015-05-31 (day precision). PeptideScanner associated the retained record with the identity slug nesiritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT01946568 at 2026-11-16T17:37:42.807Z. Its registry update date was 2015-06-23, and PeptideScanner's reviewed identity mapping was dalbavancin.
PubMed lists PMID 25851250 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-04-08 (day precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT01317004 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-06-22, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PubMed lists PMID 25216888 in Journal of the American Pharmacists Association : JAPhA as Journal Article, with publication-date metadata of 2014 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug albiglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PeptideScanner retained ClinicalTrials.gov record NCT00986817 at 2026-11-15T21:47:40.408Z. Its registry update date was 2015-06-15, and PeptideScanner's reviewed identity mapping was terlipressin.
PeptideScanner retained ClinicalTrials.gov record NCT00616460 at 2026-11-15T21:58:19.888Z. Its registry update date was 2015-06-12, and PeptideScanner's reviewed identity mapping was bivalirudin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090854 with status AP dated 2015-06-12, and names eptifibatide among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT00947882 at 2026-11-15T21:52:09.579Z. Its registry update date was 2015-06-08, and PeptideScanner's reviewed identity mapping was degarelix.
DailyMed lists Structured Product Labeling version 12 for the reviewed Dulaglutide label family with a published date of 2015-06-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 091555 with status AP dated 2015-06-05, and names eptifibatide among the application record's active ingredients.
PeptideScanner retained PubMed bibliographic metadata for PMID 25731775 at 2026-07-30T21:43:30.952Z. PubMed recorded a metadata revision date of 2015-06-02 and an Entrez history date of 2015-03-04. PeptideScanner associated this retained record with the identity slug ghk-cu. These dates describe PubMed metadata history, not the article's original publication date.
PubMed lists PMID 25843163 in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology as Case Reports, Letter, with publication-date metadata of 2015-04-03 (day precision). PeptideScanner associated the retained record with the identity slug mecasermin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
The official Drugs@FDA dataset lists original submission 1 for ANDA 201831 with status AP dated 2015-05-28, and names desmopressin acetate among the application record's active ingredients.
PeptideScanner retained PubMed bibliographic metadata for PMID 25998595 at 2026-07-30T21:43:30.962Z. PubMed recorded a metadata revision date of 2015-05-22 and an Entrez history date of 2015-05-23. PeptideScanner associated this retained record with the identity slug exenatide. These dates describe PubMed metadata history, not the article's original publication date.
PeptideScanner retained ClinicalTrials.gov record NCT02315001 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-20, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01519518 at 2026-11-15T21:58:19.888Z. Its registry update date was 2015-05-13, and PeptideScanner's reviewed identity mapping was bivalirudin.
The official Drugs@FDA dataset lists original submission 1 for NDA 201849 with status AP dated 2015-05-08, and names glucagon hydrochloride among the application record's active ingredients.
The Federal Register published notice 2015-10994, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; SIGNIFOR,” and PeptideScanner's exact reviewed identity mapping connects the document to Pasireotide.
The Federal Register published notice 2015-11000, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; GATTEX,” and PeptideScanner's exact reviewed identity mapping connects the document to Teduglutide.
The Federal Register published notice 2015-11003, attributed to FDA and its parent HHS department, on 2015-05-07. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OVUGEL,” and PeptideScanner's exact reviewed identity mapping connects the document to Triptorelin.
PeptideScanner retained ClinicalTrials.gov record NCT00780858 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-05-06, and PeptideScanner's reviewed identity mapping was ganirelix.
PeptideScanner retained ClinicalTrials.gov record NCT00835848 at 2026-07-30T21:42:40.790Z. Its registry update date was 2015-05-05, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00527488 at 2026-11-15T21:52:09.579Z. Its registry update date was 2015-05-04, and PeptideScanner's reviewed identity mapping was degarelix.
PeptideScanner retained ClinicalTrials.gov record NCT00500110 at 2026-07-30T21:42:40.792Z. Its registry update date was 2015-04-28, and PeptideScanner's reviewed identity mapping was leuprolide.
The Federal Register published notice 2015-09299, attributed to FDA and its parent HHS department, on 2015-04-22. Its official title is “Determination That OXYTOCIN in 5% Dextrose Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Oxytocin.
The official Drugs@FDA dataset lists original submission 1 for ANDA 090218 with status AP dated 2015-04-16, and names glatiramer acetate among the application record's active ingredients.
PeptideScanner retained ClinicalTrials.gov record NCT01473589 at 2026-07-30T21:42:40.788Z. Its registry update date was 2015-04-16, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT01473602 at 2026-07-30T21:42:40.804Z. Its registry update date was 2015-04-16, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00673387 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT01077323 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00392925 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was metreleptin.
PeptideScanner retained ClinicalTrials.gov record NCT01297062 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT02416271 at 2026-07-30T21:42:40.803Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was teriparatide.
PeptideScanner retained ClinicalTrials.gov record NCT00375492 at 2026-07-30T21:42:40.801Z. Its registry update date was 2015-04-07, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00500370 at 2026-07-30T21:42:40.804Z. Its registry update date was 2015-04-07, and PeptideScanner's reviewed identity mapping was exenatide.
PeptideScanner retained ClinicalTrials.gov record NCT00215683 at 2026-11-15T21:52:09.579Z. Its registry update date was 2015-04-01, and PeptideScanner's reviewed identity mapping was degarelix.
DailyMed lists Structured Product Labeling version 3 for the reviewed Pramlintide label family with a published date of 2015-03-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00004426 at 2026-07-30T21:43:54.469Z. Its registry update date was 2015-03-26, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00004436 at 2026-07-30T21:43:54.456Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00004438 at 2026-07-30T21:43:54.452Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT01755572 at 2026-07-30T21:43:54.457Z. Its registry update date was 2015-03-25, and PeptideScanner's reviewed identity mapping was liraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT01626560 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was daptomycin.
PeptideScanner retained ClinicalTrials.gov record NCT01682642 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-03-20, and PeptideScanner's reviewed identity mapping was goserelin.
DailyMed lists Structured Product Labeling version 11 for the reviewed Dulaglutide label family with a published date of 2015-03-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00772447 at 2026-11-15T22:01:45.056Z. Its registry update date was 2015-03-09, and PeptideScanner's reviewed identity mapping was daptomycin.
DailyMed lists Structured Product Labeling version 2 for the reviewed Pramlintide label family with a published date of 2015-03-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00381342 at 2026-07-30T21:43:54.470Z. Its registry update date was 2015-02-23, and PeptideScanner's reviewed identity mapping was exenatide.
DailyMed lists Structured Product Labeling version 10 for the reviewed Dulaglutide label family with a published date of 2015-01-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
PeptideScanner retained ClinicalTrials.gov record NCT00631527 at 2026-07-30T21:43:54.453Z. Its registry update date was 2015-01-29, and PeptideScanner's reviewed identity mapping was leuprolide.
PeptideScanner retained ClinicalTrials.gov record NCT00451451 at 2026-11-16T17:42:50.457Z. Its registry update date was 2015-01-26, and PeptideScanner's reviewed identity mapping was glatiramer-acetate.
PeptideScanner retained ClinicalTrials.gov record NCT00748072 at 2026-11-15T22:08:31.832Z. Its registry update date was 2015-01-13, and PeptideScanner's reviewed identity mapping was vasopressin.
PeptideScanner retained PubMed bibliographic metadata for PMID 25575154 at 2026-07-30T21:44:40.387Z. PubMed recorded a metadata revision date of 2015-01-10 and an Entrez history date of 2015-01-10. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.
DailyMed lists Structured Product Labeling version 1 for the reviewed Pramlintide label family with a published date of 2015-01-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 8 for the reviewed Dulaglutide label family with a published date of 2015-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.